True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system for rare diseases, today announced that it has been selected to make an oral presentation of its lead antibody drug candidate and novel mechanism for targeting the Classical Complement pathway at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10, 2013 in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
